Blood glucose lowering and toxicological effects of zinc (II) complexes with maltol, threonine, and picolinic acid

Research Communications in Molecular Pathology and Pharmacology

Volumn 112, Issue 1-4, 2002, Pages 91-104

  Kojima, Yoshitane ^a   Yoshikawa, Yutaka ^a   Ueda, Eriko ^a   Kondo, Mayuko ^a   Takahashi, Saeko ^b   Matsukura, Takefumi ^b   Sakurai, Hiromu ^c   Hiroi, Toyoko ^d   Imaoka, Susumu ^d   Funae, Yoshihiko ^d  

^a Osaka Prefecture University   (Japan)

^b Technology Department / Yonezawa Hamari Chemicals Ltd 2 4300 18   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^d OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Blood glucose normalizing effect; Cytochrome P450; KK Ay mice; L threonine; LD50; Maltol; Picolinic acid; Toxicity studies; Zinc (II) complexes

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; GLUCOSE; HEMOGLOBIN A1C; MALTOL; PICOLINIC ACID; THREONINE; ZINC CHLORIDE; ZINC COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; LD 50; LIVER MICROSOME; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2E1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; LETHAL DOSE 50; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED ICR; MICROSOMES, LIVER; PICOLINIC ACIDS; PYRONES; THREONINE; ZINC COMPOUNDS;

EID: 12144289133     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. th ed., New York, 1971; pp.122-123.
2. Blostein-Fuji A., DiSilvestro R. A., Frid D., Katz C., and Malarkey W., Short-term zinc supplementation in woman with non-insulin-dependent diabetes mellitus: effects on plasma 5'-nucleotidase activities, insulin-like growth factor I concentrations, and lipoprotein oxidation rates in vitro., Am. J. Clin. Nutr. 1997; 66, 639-642.
3. Chen M. D., Liou S. J., Lin P. Y., Yang V. C., Alexander P. S., and Lin W. H., Effects of Zinc Supplementation on the Plasma Glucose Level and Insulin Activity in Genetically Obese (ob/ob) Mice., Biol. Trace Elem. Res. 1998; 61, 303-311.
4. Coulston L., Dandona P., Insulin-like Effect of Zinc on Adipocytes., Diabetes 1980; 29, 665-667.
5. nd ed., Cambridge: Cambridge University Press., 1959; p.318.
6. Funae Y., Imaoka S., and Shimojo N., Purification and characterization of diabetes-inducible cytochrom P-450., Biochem. Int. 1988; 16, 503-509.
7. Imaoka S., Terano Y., and Funae Y., Changes in the amount of cytochrome P450s in rat microsomes with starvation., Arch. Biochem. Biophys. 1990; 278, 168-178
8. th ed., New York, 1996; pp.3421.
9. Lowry O. H., Rosebrogh N. J., Farr A. L., and Randall R. J., J. Biol. Chem. 1951; 193, 265-275.
10. Lucas D., Farez C., Bardou L. G., Vaisse J., Attali J. R., and Valensi P., Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation., Fundam. Clin. Pharmacol. 1998; 12, 553-8
11. Morimoto M., Hagbjork A. L., Nanji A. A., Ingelman-Sundberg M., Lindros K. O., Fu P. C., Albano E., and French S. W., Role of cytochrome P450 2E1 in alcoholic liver disease pathogenesis., Alcohol 1993; 10, 459-464.
12. Nebert D. W., Puga A., Vasiliou V., and Ann. N. Y., Role of the Ah receptor and the dioxin-inclucible [Ah] gene battery in toxicity, cancer, and signal transduction., Ann NY Acad. Sci. 1993; 685, 624-640.
13. Omura T., and Sato R., The carbon monoxide-binding pigment of liver microsomes II. Solubilization, purification, and properties., J. Biol. Chem. 1964; 239, 2379-2385.
14. Sharon F. A., and Carla G. T., Dietary Zinc Supplementation Attenuates Hyperglycemia in db/db Mice., Exp. Biol. Med. 2001; 226, 43-51.
15. Shisheva A., Gefel D., and Schechter Y., Insulinlike effects on zinc ion in vitro and in vivo., Diabetes 1992; 41, 982-988.
16. Song M. K., Rosenthal M. J., Hong S., Harris D. M., Hwang I., Yip I., Golub M. S., Ament M. E., and Go V. L. W., Synergistic Antidiabetic Activities of Zinc, Cyclo (His-Pro), and arachidonic acid., Metabolism 2001; 50, 53-59.
17. Thompson W., and Weil C., On the construction of tables for moving average interpolation., Biometrics 1952; 8, 51-54
18. th ed. New York and London: Academic Press., 1977; pp.196-242.
19. Weil C., Tables for convenient calculation of median effective dose (LD50 and ED50) and instructions in their use. Biometrics 1952; 8, 249-263.
20. Williams M. W., Hoeschele J. D., Turner J. E., Jacobson K. B., Christie N. T., Paton C. L., Smith L. H., and Lee E. H., Chemical softness and acute metal toxicity in mice and drosophila., Toxicol. Appl. Pharmacol., 1982; 63, 461-469.
21. 4) Coordination Mode., Chem. Lett. 2000; 874-875.
22. y mice with type 2 diabetes mellitus., Biochem. Biophys. Res. Commun. 2001; 281, 1190-1193.
23. 2) Coordination Mode., Chem. Pharm. Bull. 2001; 49, 652-654.
24. Yoshikawa Y., Ueda H., Kawabe K., Miyake H., Sakurai H., and Kojima Y., Development of New Insulin-mimetic Zinc (II) Complexes with Picolinic acid derivatives: Structure, in vitro, and in vivo Studies., J. Biol. Inorg. Chem., 2002; 7, 68-73.